Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients

Journal of Nephrology

Volumn 24, Issue 4, 2011, Pages 515-521

  Uchida, Junji ^a   Machida, Yuichi ^a   Iwai, Tomoaki ^a   Iguchi, Taro ^a   Kamada, Yoshiko ^a   Naganuma, Toshihide ^a   Kumada, Norihiko ^a   Kim, Taku ^a   Kawashima, Hidenori ^a   Nakatani, Tatsuya ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II receptor blocker; Low grade albuminuria; Renal transplantation

Indexed keywords

ALBUMIN; ANGIOTENSIN 1 RECEPTOR; CREATININE; CYCLOSPORIN; POTASSIUM; TACROLIMUS; VALSARTAN;

ADULT; ALBUMINURIA; ANEMIA; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HUMAN; HYPOTENSION; KIDNEY TRANSPLANTATION; MALE; OBSERVATIONAL STUDY; OPEN STUDY; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL;

ADULT; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HEMATOCRIT; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POTASSIUM; PROSPECTIVE STUDIES; RANDOM ALLOCATION; TETRAZOLES; VALINE;

EID: 79960294780     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2011.6235     Document Type: Article

References (22)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
2. Verhave JC, Gansevoort RT, Hillege HL, Bakker SJ, De Zeeuw D, de Jong PE; PREVEND Study Group. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl. 2004;92:S18-S21.
3. Hillege HL, Fidler V, Diercks GF, et al; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777-1782.
4. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension. 2000;35:898-903.
5. Halimi JM, Buchler M, Al-Najjar A, et al. Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients. Am J Transplant. 2007;7:618-625.
6. Arnlöv J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005;112:969-975.
7. Gerstein HC, Mann JF, Yi Q, et al; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-426.
8. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000;57:307-313.
9. Asselbergs FW, Diercks GF, Hillege HL, et al. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110:2809-2816.
10. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110:921-927.
11. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:198-202.
12. Iñigo P, Campistol JM, Saracho R, et al. Renoprotective effects of losartan in renal transplant recipients: results of a retrospective study. Nephron Clin Pract. 2003;95:c84-c90.
13. Omoto K, Tanabe K, Tokumoto T, Shimmura H, Ishida H, Toma H. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. Transplantation. 2003;76:1170-1174.
14. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia. 1996;39:587-593.
15. Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR: revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982-992.
16. Casiraghi F, Aiello S, Remuzzi G. Transplant tolerance: progress and challenges. J Nephrol. 2010;23:263-270.
17. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
18. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.
19. Lindholm LH, Ibsen H, Dahlöf B, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
20. Dounaevskaia V, Yan AT, Charytan D, et al. The management of left ventricular systolic dysfunction in patients with advanced chronic kidney disease. J Nephrol. 2010 Mar 22 (in press).
21. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol. 2006;17:889-899.
22. Klaassen RJ, van Gelder T, Rischen-Vos J, Deinum J. Man in't Veld AJ, Weimar W. Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with posttransplant erythrocytosis. Transplantation. 1997;64:780-782.